Loading
Life sciences · Journal article
Phytotherapy Research · October 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Obesity is a chronic, recurrent, and progressive disease caused by energy imbalance. N 6 ‐methyladenosine (m 6 A) modification regulates fat thermogenesis, potentially counteracting obesity. Mogroside V (MV) is a triterpene glycoside extracted from Siraitia grosvenorii and has shown beneficial effects in models of obesity. However, its underlying mechanism remains unknown. The objective of this study is to investigate the effects of MV on adipose thermogenesis and explore the mechanism of m 6 A modifications in mediating these effects. Mitochondrial respiration analysis, histological and molecular biological methods were used to investigate the thermogenesis in differentiated C3H10T1/2 brown adipocytes and adipose tissue in high‐fat diet (HFD)‐fed mouse models, respectively. Stable cell models with overexpression or knockdown of fat mass and obesity‐associated protein (FTO) were generated to investigate the effects of FTO on m 6 A modification and thermogenesis in brown adipocytes. Methylated RNA immunoprecipitation‐quantitative‐PCR (MeRIP‐qPCR) and RIP‐qPCR analysis were used to reveal the potential downstream molecular targets of FTO. MV improved HFD‐induced obesity and metabolic dysfunction in mice. MV also increased uncoupling protein 1 (UCP1) expression in brown adipose tissue and enhanced mitochondrial respiration and expression of peroxisome proliferator activated receptor γ coactivator 1α (PGC1α) and UCP1 in differentiated C3H10T1/2 cells. Further analysis of the relevant molecular mechanisms showed that MV suppressed FTO expression, thereby increasing m 6 A modification of LETM1 domain‐containing protein 1 ( Letmd1 ) mRNA. The m 6 A‐modified Letmd1 transcript was recognized by the m 6 A reader YTH domain‐containing protein 2 (YTHDC2), thereby increasing the stability of Letmd1 mRNA. The increased Letmd1 mRNA levels were correlated with increased LETMD1 protein abundance, which subsequently enhanced the expression of PGC1α and UCP1, ultimately promoting brown adipocyte thermogenesis. MV promoted brown adipocyte thermogenesis through the FTO‐m 6 A‐LETMD1‐UCP1 axis, suggesting a potential therapeutic strategy for obesity.